KLS Keeping Law Simple Legislation in plain English

Straight-ahead summaries built from the official bill text. We keep the source links front and center and leave the decision up to you.

Back to California

AB-1320 • 2026

California Affordable Drug Manufacturing Act of 2020: opioid antagonists.

California Affordable Drug Manufacturing Act of 2020: opioid antagonists.

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor
Patterson
Last action
2026-02-02
Official status
From committee: Filed with the Chief Clerk pursuant to Joint Rule 56.
Effective date
Not listed

Plain English Breakdown

The official summary does not provide information on enforcement mechanisms or penalties for violating the new rules.

California Affordable Drug Manufacturing Act of 2020: Opioid Antagonists

This law prohibits California state agencies from awarding non-competitive contracts to companies involved in multistate settlements over the opioid crisis for purchasing or manufacturing opioid antagonists, and makes such contracts void and unenforceable.

What This Bill Does

  • It stops California state agencies from awarding non-competitive contracts to companies that have entered into multistate settlement agreements for their role in contributing to the opioid epidemic when buying or making opioid antagonists.
  • It declares any contract violating this rule void and unenforceable, even if it was made before January 1, 2026.

Who It Names or Affects

  • California state agencies
  • Companies involved in multistate settlements for their role in the opioid epidemic

Terms To Know

Opioid antagonist
A drug that blocks or reverses the effects of opioids, used to treat overdose.
Multistate settlement agreement
An agreement between multiple states and a company over legal issues related to the opioid crisis.

Limits and Unknowns

  • The law does not specify what happens if a state agency mistakenly awards a non-competitive contract.
  • It is unclear how this law will affect existing contracts made before January 1, 2026.
  • There are no details on enforcement mechanisms or penalties for violating the new rules.

Bill History

  1. 2026-02-02 California Legislative Information

    From committee: Filed with the Chief Clerk pursuant to Joint Rule 56.

  2. 2026-01-31 California Legislative Information

    Died pursuant to Art. IV, Sec. 10(c) of the Constitution.

  3. 2025-04-29 California Legislative Information

    In committee: Set, first hearing. Failed passage. Reconsideration granted.

  4. 2025-03-13 California Legislative Information

    Referred to Com. on HEALTH.

  5. 2025-02-24 California Legislative Information

    Read first time.

  6. 2025-02-22 California Legislative Information

    From printer. May be heard in committee March 24.

  7. 2025-02-21 California Legislative Information

    Introduced. To print.

Official Summary Text

AB 1320, as introduced, Patterson.
California Affordable Drug Manufacturing Act of 2020: opioid antagonists.
Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) or its departments to enter into partnerships, in consultation with other state departments as necessary, to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs. For purposes of implementing these provisions, existing law authorizes CHHSA and its departments, including the Department of Health Care Access and Information, to enter into exclusive or nonexclusive contracts on a bid or negotiated bases. Existing law exempts these contracts entered into by CHHSA and its departments from the review or approval of any division of the Department of General
Services as well as from provisions pertaining to bidding and awarding of state contracts.
This bill would prohibit a state agency from awarding a contract, pursuant to the above provisions, on a noncompetitive basis for the purchase or acquisition of an opioid antagonist, as defined, with a contractor that has entered into a multistate settlement agreement for its role in contributing to the opioid epidemic. The bill would make a contract void and unenforceable for a violation of this provision and apply those provisions retroactively to contracts entered into before January 1, 2026.

Current Bill Text

Read the full stored bill text 
Download Bill PDF